Botulinum toxin: A new dimension in the treatment of lower urinary tract dysfunction

Urology

Volumn 64, Issue 1, 2004, Pages 2-8

  Rajkumar, G N ^a   Conn, I G ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ACETYLCHOLINE RELEASE; BINDING AFFINITY; BLEPHAROSPASM; CHRONIC PAIN; CLINICAL TRIAL; CYTOSOL; DERMATOMYOSITIS; DETRUSOR DYSSYNERGIA; DOSE RESPONSE; DRUG BINDING; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UTILIZATION; DYSPHAGIA; EXOCYTOSIS; HEMIFACIAL SPASM; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; INJECTION; MICTURITION DISORDER; MUSCLE WEAKNESS; NERVE ENDING; NEUROGENIC BLADDER; NEUROMUSCULAR SYNAPSE; NEUROPATHY; NONHUMAN; PAIN; PRIORITY JOURNAL; PTOSIS; REVIEW; RISK ASSESSMENT; SEROTYPE; URETHRA DISEASE; VISUAL IMPAIRMENT; XEROSTOMIA;

ACETYLCHOLINE; ANIMALS; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MUSCLE HYPERTONIA; NEUROMUSCULAR AGENTS; PAIN; PRESYNAPTIC TERMINALS; RATS; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE; URINATION DISORDERS;

EID: 3042697973     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.03.007     Document Type: Review

References (51)

1. Van Ermengem E: Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Zeitschrift für Hygiene und Infektionskrankheiten 26:1-56, 1897; translation reprinted in Rev Infect Dis 1: 701-719, 1979
2. Van Ermengem E: Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Zeitschrift für Hygiene und Infektionskrankheiten 26:1-56, 1897; translation reprinted in Rev Infect Dis 1: 701-719, 1979
3. Comella C.L., Brin M., Jankovic J. Biochemistry of botulinum toxin type B. Neurology. 55:(suppl 5):2000;22-28
4. Dolly O. Synaptic transmission inhibition of neurotransmitter release by botulinum toxins. Headache. 43:(suppl 1):2003;S16-S24
5. Dickson E.C., Shevky R. Botulism studies on the manner in which the toxin of Clostridium botulinum acts upon the body. II. The effect on the voluntary nervous system. J Exp Med. 38:1923;327-346
6. Burgen A.S.V., Dickens F., Zatman L.J. The action of botulinum toxin on the neuromuscular junction. J Physiol. 109:1949;10-24
7. Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 87:1980;1044-1049
8. Das Gupta B.R., Sugiyama H. Role of a protease in natural activation of Clostridium botulinum neurotoxin. Infect Immun. 6:1972;587-590
9. Schiavo G., Rossetto O., Santucci A., et al. Botulinum neurotoxins are zinc proteins. J Biol Chem. 267:1992;23479-23483
10. Pellizzari R., Rossetto O., Schiavo G., et al. Tetanus and botulinum neurotoxins mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci. 354:1999;259-268
11. Dolly J.O., Black J., Williams R.S., et al. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalisation. Nature. 307:1984;457-460
12. Stecher B., Weller U., Habermann E., et al. The light chain but not the heavy chain of botulinum type A toxin inhibits exocytosis from permeabilised adrenal chromaffin cells. FEBS Lett. 255:1989;318-325
13. Hayashi T., McMahon H., Yamasaki S., et al. Synaptic vesicle membrane fusion complex action of clostridial neurotoxins on assembly. EMBO J. 13:1994;5051-5061
14. Angaut-Petit D., Molgo J., Comella J.X., et al. Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin morphological and electrophysiological features. Neuroscience. 37:1990;799-808
15. DePaiva A., Neunier F.A., Molgo J., et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 96:1996;3200-3205
16. Zwirner P., Murry T., Swenson M., et al. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia acoustic, aerodynamic and videoendoscopic findings. Laryngoscope. 102:1992;400-406
17. Brin MF, Blitzer A, Stewart C, et al. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin: review and technical aspects, in Blitzer A, Brin MF, Sasaki CT, et al(Eds): Neurological Disorders of the Larynx. New York, Thieme, 1992, pp 214-228
18. Rosales R.L., Arimura K., Ikenaga S., et al. Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve. 19:1996;488-496
19. Filippi G.M., Ericco P., Santarelli R., et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 113:1993;400-404
20. Tsui J.K., Eisen A., Mak E., et al. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci. 12:1985;314-316
21. Tsui J.K., Eisen A., Stoessl A.J., et al. Double blind study of botulinum toxin in spasmodic torticollis. Lancet. 2:1986;245-247
22. Zermann D., Ishigooka M., Schubert J., et al. Perisphincteric injection of botulinum toxin type A a treatment option for patients with chronic prostatic pain? Eur Urol. 38:2000;393-399
23. Hoffman G.E., Lyo D. Anatomical markers of activity in neuroendocrine systems are we all 'fos-ed out'? J Neuroendocrinol. 14:2002;259-268
24. McLellan K., Das R.E., Ekong T.A., et al. Therapeutic botulinum type A toxin factors affecting potency. Toxicon. 34:1996;975-985
25. Blakie J.D., Lees A.J. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neursurg Psychiatry. 53:1990;640-643
26. Sloop R.R., Cole B.A., Escutin R.O. Human response to botulinum toxin injection type A compared with type B. Neurology. 49:1997;189-194
27. Greene P., Fahn S., Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 9:1994;213-217
28. Greene P., Kang U., Fahn S., et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 40:1990;1213-1218
29. Grosse J., Kramer G., Schurch B., et al. Repeat detrusor injections of botulinum A toxin in patients with neurogenic lower urinary tract dysfunction do not cause increased drug tolerance. Neurourol Urodyn. 21:2002;275-283
30. Sheean G.L., Lees A.J. Botulinum toxin type F in the treatment of torticollis clinically resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry. 59:1995;601-607
31. Clinical use of botulinum toxin. Conference statement, National Institutes of Health Consensus Development (Nov 12-14, 1990). Arch Neurol 48:1294-1298, 1991
32. Girlanda P., Vita G., Nicolosi C. Botulinum toxin therapy distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry. 55:1992;844-845
33. Del Popolo G. Botulinum A toxin in the treatment of detrusor hyperreflexia. Neurourol Urodyn. 20:2001;522-524
34. Wyndaele J.J., Van Dromme S.A. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 40:2002;599-600
35. Probst TE, Heise H, Heise P, et al. Rare immunologic side effects of botulinum toxin therapy: brachial plexus neuropathy and dermatomyositis. Move Dis 17(suppl 5): 49, 2002
36. Baumann L.S., Halem M.L. Systemic adverse effects after botulinum toxin type B (Myobloc) injections for the treatment of palmar hyperhidrosis. Arch Dermatol. 139:2003;226-227
37. Schurch B., Hodlet J., Rodic B. Botulinum A toxin as a treatment of detrusor sphincter dyssynergia in patients with spinal cord injury MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry. 63:1997;474-476
38. Dykstra D.D., Sidi A.A., Scot A.B., et al. Effects of botulinum toxin on detrusor sphincter dyssynergia in spinal cord injury patients. J Urol. 139:1988;919-922
39. Dykstra D.D., Sidi A.A. Treatment of detrusor sphincter dyssynergia with botulinum A toxin a double blind study. Arch Phys Med Rehabil. 71:1990;24-26
40. Petit H., Wiart L., Gaujard E., et al. Botulinum A toxin treatment for detrusor sphincter dyssynergia in spinal cord disease. Spinal Cord. 35:1998;91-94
41. Schurch B., Hauri D., Rodic B., et al. Botulinum A toxin as a treatment of detrusor sphincter dyssynergia a prospective study in 24 spinal cord injury patients. J Urol. 155:1996;1023-1029
42. Phelan M.W., Franks M., Somogyi G.T., et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol. 165:2001;1107-1110
43. Radziszewski P., Dobronski P., Borkowski A. Treatment of the non-neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A a pilot study. Neurourol Urodyn. 20:2001;410-412
44. Franks M.E., Somogyi G.T., Phelan M.W., et al. Botulinum toxin injection into the bladder wall decreases acetylcholine (Ach) and norepinephrine (NE) release potential treatment for an overactive bladder (abstract). J Urol. 163:(suppl 4):2000;42
45. Dykstra D., Enriquez A., Valley M. Treatment of overactive bladder with botulinum toxin type B a pilot study. Int Urogynecol J Pelvic Floor Dysfunct. 14:2003;424-426
46. Schurch B., Stohrer M., Kramer G., et al. Botulinum A toxin for treating detrusor hyperreflexia in spinal cord injured patients a new alternative to anticholinergic drugs? Preliminary results. J Urol. 164:2000;692-697
47. Stohrer M., Schurch B., Kramer G., et al. Botulinum A toxin to treat detrusor hyperreflexia in spinal cord injured patients a long term follow up. ANZ J Surg. 73:2003;A142-A143
48. Richter R., Schaaf V. Botulinum A toxin for therapy of detrusor hyperreflexia in neurogenic bladders (GER) (abstract). Aktuel Urol. 33:2002;141-142
49. Dykstra D.D., Pryor J., Goldish G. Use of botulinum toxin type B in detrusor hyperreflexia in a patient with multiple sclerosis a case study. Arch Phys Med Rehab. 84:2003;1399-1400
50. Zermann D.H., Ishigooka M., Schubert J., et al. Trigonum and bladder base injection of severe urgency-frequency syndrome refractory to conservative medical treatment and electrical stimulation. Neurourol Urodyn. 20:2001;412-413
51. Bentivoglio A., Maria G., Destito A. Type A botulinum toxin in the striated urethral sphincter for the treatment of voiding dysfunction due to chronic nonbacterial prostatitis (abstract). Mov Disord. 15:(suppl 2):2000;42-43